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INTRODUCTION 
Coronary artery heart disease is a global health problem and also an 
important cause of death in all age groups.1 Studies are being done in both 
developed and developing countries to find its risk factors. The results of various 
studies have revealed atherosclerosis of the coronary vessels due to altered lipid 
profile is the commonest mechanism in most of the patients. In many patients the 
risk factors are identified only when they succumbed to life threatening events 
like acute coronary syndrome.  
Screening for diabetes and hypertension identifies pre diabetic and pre 
hypertensive states. Prevention of the emergence of these risk factors constitutes 
the primordial prevention. In the same way, the overt hypothyroidism has its 
subclinical counterpart which is also being proposed as a risk factor for coronary 
artery heart disease. 
Subclinical hypothyroidism is a common problem and occurs in 3% to 8% 
of the population and 2-5% of SCH carries a risk of progression to overt 
hypothyroidism in every year.2,3 Many prospective studies have given varied 
results regarding its association with altered lipid profile. There is a significant 
association between subclinical hypothyroidism and increased risk of coronary 
artery heart disease, cardiac failure and death with higher TSH levels, 
particularly in those patients with TSH levels ≥ 10.0 m IU/L.⁴ 
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In this study thyroid function tests and lipid profile were done in ACS 
patients to know the prevalence of the subclinical hypothyroidism and the 
association between them as an attempt to identify the emergence of 
hypothyroidism as a risk factor for acute coronary syndrome. 
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REVIEW OF LITERATURE                                                   
EPIDEMIOLOGY 
Global burden of Coronary Heart Diseases              
 In the U.S., Coronary Heart Disease is the leading cause of mortality in 
adult population accounting for nearly one third of all deaths in the persons over 
the age of 35 years.5 According to 2016 Heart Disease and Stroke Statistics 
update of the AHA report, overall death rate from CHD was 102.6 per 100,000.6 
Patients were asymptomatic for a prolonged period in spite of the evidence of 
CHD with the progression of atherosclerosis over many years. Non-obstructive 
CHD patients when comparing with patients without the evidence of CHD had 
worst prognosis even though they are asymptomatic.7, 8    
 Only a few population-based studies have shown recent trends in the 
incidence of MI. In many time periods (1971–1982, 1982–1992, 9 1975–1997, 10 
1994–1999, 11 and 1987–2006) observational studies were done. They have found 
no reduction in the incidence of MI.12 After 2000 AD, the advent of the more 
sensitive troponin assays (comparing with CK-MB) helped to diagnose MI                  
even though the area of infarct was small. This could have potentially masked the 
actual reduction in MI incidence during these time periods.13  
 Several studies have been done to know the influence of sex and race on 
the incidence of MI. The Atherosclerosis Risk in Communities (ARIC) study 
concentrated on the risk of CHD events in 360,000 residents aged 35–74 years in 
four communities:  
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Forsythe County, North Carolina; Jackson, Mississippi; Minneapolis, 
Minnesota; and Washington County, Maryland.14, 15  
This study was done during the period between 1987 and 1996. A definite 
or probable MI was diagnosed in 14,942 hospitalized patients. The age-adjusted 
incidence of hospitalized MI was highest in black men and lowest among white 
women. 
The age-adjusted incidence of first episode of MI was relatively stable 
during 1987–1996 in males and females for white people. Also, there was a non-
significant trend to increase by1.1% in men and 1.7%in women per year. 
In black people there was a significant increase in the trend (4.1% in men 
and 3.9% in women per year). The study also showed a reduction in the 
incidence in recurrent MI in both genders (−1.9% in men and −2.1% in women 
per year). Post- MI mortality rate had decreased significantly during the period 
between 1987–1996 (by −6.1% in men and −6.2% in women). Although 
coronary atherosclerosis and ACS have male preponderance, as a result of dietary 
habits, smoking and mental stress the incidence of it is increasing in women.  
ACS trends in India   
Mortality at early age was noted in many studies of migrant Indians in the 
1980s. It was the INTERHEART study (a large international case-control study 
across 52 nations) that confirmed the early age of onset of incident myocardial 
infarction among patients from South Asia.16 In this study, the median age of MI 
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in South Asians was 52 years in comparison with 62 years in the European origin 
cohort. This study found that the equal presence of usual cardiovascular risk 
factors of elderly persons in the young South Asians and occurrence of early 
onset of myocardial infarction.  
According to the Global Burden of Disease study (2010), 24.8% of all 
deaths in India were attributable to Cardio Vascular Diseases.17 The age-
standardized CVD mortality rate of 272 per 100000 population in India was 
found to be higher than the global average of 235 per 100000 population.17 
Ischemic heart disease (IHD) and stroke had been the important causes for the 
majority of deaths due to cardio vascular diseases in India (83%). IHD had 
predominance over all other causes. The years of life lost attributable to CVD in 
India had increased by 59% from 1990 to 2010 (23.2 million to 37 million).17 
Risk factors burden in India 
In 2013, the International Diabetes Federation found an estimate of 
diabetics as 65.1 million in India and most of them were adults of working age.17 
It has been estimated that the number of diabetics will increase to 101 million by 
2030.17 
In the urban population of India, the prevalence of diabetes mellitus has 
nearly doubled in the past 20 years, from 9% to 17% and in rural population it 
has increased to almost four times, from 2% to 9% .17   
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Recently, it has been estimated that 275 million persons aged ≥15 years 
consume tobacco in India.18 The deaths associated with tobacco in India are high.  
It is estimated that 1 million deaths are caused by it annually.19 
The prevalence of hypertension in adult Indians is found to be 30% (34% 
in urban areas and 28% in rural areas).20 The number of hypertensive persons is 
expected to double from 118 million in 2000 to 213.5 million by 2025.21 
National Sample Survey Organization surveys showed that, from 1972 to 
2000, fat intake of Indians increased from 24 to 36 g/day in rural population; and 
from 36 to 50 g/day in urban population. 22 
 In the ICMR-INDIAB study, at least 1 altered lipid fraction was found in 
majority of the people. Only 20% had their lipid profile (total cholesterol, 
triglycerides, LDL-C and HDL-C) within the normal range.23 
                    Diagnosis of Acute Coronary Syndrome                                        
 The Acute Coronary Syndrome (ACS) is a broad term refers to any 
group of clinical symptoms that occurs due to acute myocardial ischemia and 
covers the following clinical conditions: 
 Unstable angina (UA),  
 Non ST-segment elevation myocardial infarction (NSTEMI) and 
 ST-segment elevation myocardial infarction (STEMI)  
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Unstable angina (UA) and NSTEMI 
Cause: 
Partial or intermittent occlusion of coronary artery 
The clinical presentation   
 (1) Chest pain at rest (usually lasting >20 minutes) 
 (2)  New-onset of severe chest pain (within two months) and 
 (3)  Chest pain that increases in intensity, duration, frequency, or any 
combination of  these factors. 
Both NSTEMI and unstable angina have similar pathophysiologic origins 
and clinical presentations but their clinical severity differ.  
NSTEMI is diagnosed when the ischemia is sufficiently severe enough to 
damage myocardium resulting in the release of cardiac biomarkers into the 
circulation. (Cardiac specific troponins T/I or Creatine Kinase - MB). The patient 
is diagnosed as a case of UA if cardiac bio markers are not released in blood. The 
differential diagnosis of UA, NSTEMI and STEMI is shown in Fig 1.       
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DIAGNOSTIC FINDINGS 
Electrocardiography 
 ST-segment depression and /or T-wave inversion on ECG - NSTEMI 
and UA 
 ST segment elevation - STEMI 
Cardiac biomarkers   
 According to European Society of Cardiology (ESC)/American College of 
Cardiology Foundation (ACCF)/American Heart Association (AHA)/World 
Heart Federation (WHF) the elevation of cardiac enzymes only states that 
myocardium has been injured. It will not point out the underlying mechanism 
which is responsible for the injury. 
Troponins:  
 According to the revised criteria of WHO (in 2000) a cardiac troponin rise 
accompanied either by typical symptoms, pathological Q waves, ST elevation or 
depression or coronary intervention is diagnostic of ACS.    
 They are regulatory proteins seen in both cardiac and skeletal muscles. 
There are three sub units: Tn I, Tn T and Tn C. Since distinction exists between 
them in the sub forms of Tn I and TnT, immuno assays have been developed to 
differentiate their origin whether from skeletal muscle or cardiac muscle. 
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Reference ranges for Troponin assay 
1. Upper percentile reference limit 
2. Coefficient of variation 
To overcome problems of imprecision seen in TnI assays at 99th percentile 
it is recommended to raise the CV a little higher. To overcome the disadvantages 
of these assays high sensitive or ultrasensitive troponin assays are recommended 
by investigators.24 Point of care assays for CK-MB, myoglobin and Troponins 
(Tn I and Tn T) are available.  
 The advantage of Troponins over other cardiac markers.   
Elevated Troponin levels can be utilized to predict adverse cardiac 
events and cardiac mortality 
Creatine Kinase–MB:  
                 Before the advent of cardiac troponins, CK-MB isoenzyme was the 
choice for the diagnosis of acute myocardial infarction. 
It appears 4-6 hours after the onset of the symptoms, with the peak at                  
24 hours and comes back to normal in 48 to 72 hours 
Two consecutive elevations above the upper normal level or single value 
twice the upper limit of normal were used as diagnostic criteria. 
Disadvantage of CK-MB: 
1.  False positive results can occur in severe trauma or myopathy. 
           To improve the specificity, CK-MB/total CK relative index can be used.25 
 A ratio more than 5 indicates cardiac origin for elevation. 
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 A ratio less than 3 indicates the source from skeletal muscle. 
 Between 3-5 is not possible to make a definitive diagnosis. 
Two isoforms occurs for CK-MB iso enzyme, CK -MB1 and CK-MB2. 
  Normally CK-MB1 level predominates in serum. CK-MB2/CK-MB1   
ratio of 1.7 is considered as a positive result. 
2.  According to a report from the multicenter GRACE registry, stating the 
clinical course of more than 10,000 patients with ACS, 
 The death rate at hospital was highest when both troponin and CK-MB 
were positive. The mortality rate was intermediate in troponin-positive/                   
CK-MB-negative patients, and lowest death rate was noted in patients in whom 
both markers were negative and in those who were troponin-negative/                 
CK-MB-positive.  
            So, isolated CK-MB elevation has limited prognostic value in patients 
with a non-ST elevation ACS. 
Myoglobin:      
It rises 2-4 hours after the onset of myocardial infarction, gets peak level 
at 6-12 hours and returns to normal within 24-36 hours. It lacks cardiac 
specificity. If serial myoglobin assay is done every 1-2 hours a rise of  25 - 40% 
is a firm indication for myocardial infarction. 
Newer cardiac biomarkers:                                                                         
They are useful to indicate prognosis  and predict of adverse cardiac events.26 
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1. B-type natriuretic peptide 
 In multiple studies, the mortality of CHD patients was found to be 
doubled when both Tn I and BNP were increased.  
2. C-Reactive protein 
 Nonspecific nature limits its use. Along with Tn I and BNP it is useful to 
predict the prognosis of ACS. 
3. Myeloperoxidase  
4. Ischemia modified albumin 
 This fraction of albumin is produced when circulating albumin gets 
contact with ischemic areas of heart. IMA levels increase within minutes of 
transient ischemia, reaches peak within 6 hours, and can remain elevated for as 
long as 12 hours. It can be measured by albumin cobalt binding assay. 
Disadvantage: 
False positive results occurs in  
 Cirrhosis of liver 
 Active infection  
 Malignancy      
 
  
     
 
circu
aorta
left c
arter
anter
caus
      
      
ATHERO
Vascula
lation. Tw
. The righ
oronary a
y branche
ior desce
es high de
              
              
SCLERO
C
r system 
o main co
t coronary
rtery give
s which s
nding arte
ath rate. M
Fig
             
             
SIS AND
ORONAR
which su
ronary arte
 artery su
s the left a
upply the 
ry is ofte
ajor blood
ure2. Blo
     
           
13 
 ACUTE
Y CIRC
pplies bl
ries (right
pplies mai
nterior de
left side 
n called 
 supply of
od supply
 CORONA
ULATION
ood to h
 and left) a
nly the rig
scending a
of the hea
as widow 
 heart is sh
 of the he
RY SYN
 
eart is ca
rise from r
ht side of
rtery and 
rt. Occlus
maker in
own in Fig
art 
DROME 
lled coro
oot of tho
 the heart.
the circum
ion of the
farction w
ure 2.      
nary 
racic 
 The 
flex 
 left 
hich 
              
 
     
14 
ATHEROSCLEROSIS 
Definition 
          The name Atherosclerosis is derived from the Greek words ‘sclerosis’ 
meaning hardening and ‘athere’ meaning gruel (accumulation of lipid). The 
process is characterized by deposition of cholesterol, infiltration by macrophages, 
proliferation of smooth muscle cells (SMC), accumulation of connective tissue 
components and thrombus formation.  
 Atherosclerosis is no longer a pathological process caused solely by the 
increased lipid content of the body. By new insight it is found to be a 
multifactorial disease. Damage of vascular endothelium and generation of 
reactive oxygen species and other free radicals have been recognized as factors 
almost in all the pathways leading to the development of atherosclerosis due to 
dyslipidemia, diabetes mellitus, hypertension or smoking.                 
 Hyperhomocysteinemia, C-reactive protein, infections like chlamydia and 
auto immune disease like systemic lupus erythematosus have arisen as new risk  
factors.   
Now, Atherosclerosis can be defined as a chronic inflammatory 
process with an autoimmune component.   Genes related to atherosclerosis and 
genetic basis of atherogenesis have been known. So, in future gene therapy will 
become a promising mode of management of atherosclerosis. Table.1 shows risk 
factors of CHD and Figure 3.shows common risk factors and their mechanisms. 
 
     
    Cl
Smo
Elev
Elev
Low
Exce
Left 
Thro
 
 
 
 
 
 
 
 
 
 
Table-1
ass 1. Mod
king 
ated total c
ated LDL-
 HDL-cho
ss fat/chol
ventricula
mbogenic
Figure
. RISK FA
ifiable 
holesterol
cholestero
lesterol 
esterol die
r hypertrop
 factors 
. 3 Risk fa
CTORS O
C
 
l 
t 
hy 
L
D
H
P
O
H
H
In
S
ctors of a
15 
F CARD
lass 2. Mo
ipoprotein
iabetes m
ypertensio
hysical ina
besity 
igh triglyc
igh homo
creased h
tress. 
theroscler
IO VASC
difiable 
 (a) 
ellitus 
n. 
ctivity 
erides 
cyseine 
s-CRP 
osis and t
ULAR D
Non
Ag
Ma
Fam
pre
heir mech
ISEASE 
- modifia
e 
le  gender 
ily histor
mature CH
anisms 
ble 
y of 
D  
     
16 
LIPID METABOLISM AND ITS ROLE IN ATHEROSCLEROSIS 
Triglycerides                                                                                       
Reduced blood levels of high density lipoprotein (HDL) and 
hypertriglyceridemia have been shown to be responsible for the genesis of 
atherosclerotic lesions.27According to the National Cholesterol Education 
Program guidelines patients having less than 1 mmol/L of HDL will have the risk 
for developing coronary vascular disease. The  Collaborative Heart Disease 
Study done  in the United Kingdom done in two places states that serum 
triglyceride levels were of more predictive value than total cholesterol for the 
determination of  the risk for coronary vascular disease. 28 These studies reported 
that triglyceride levels more than 2.25 mmol/L and LDL: HDL ratios more than 5 
were associated with a fivefold increase in the risk for cardiovascular morbidity, 
particularly in persons with a metabolic syndrome. Serum triglyceride level of 
1.7 mmol / L is considered as the upper normal limit.   
Clinical significance  
Triglyceride concentrations are usually elevated in both type 1 and type 2 
diabetes mellitus and considered as a risk factor for coronary artery heart disease. 
Excess insulin causes non enzymatic glycation of the lipoproteins, which interact 
with cytokines and growth factors, and has an important role in atherogenesis. 29 
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High Density Lipoprotein-Cholesterol                                                                               
            HDL plays vital role in the development of atherosclerosis due to its 
function in reverse cholesterol transport. Cell surface HDL receptors mediate the 
protective effects of HDL which have opened new ways for the management of 
atherosclerotic cardiovascular diseases. SR-B1, a HDL surface receptor mediates 
selective HDL cholesterol uptake. The pro atherogenic activity of LDL is also 
counteracted HDL by mobilizing cholesterol from intimal layer of arterial wall 
and transporting it to the liver for excretion into the bile. Studies have found that 
HDL may accept, transport and inactivate oxidized LDL (oxLDL). 
Clinical significance 
Evidences from experimental studies have given suggestion that SR-BI 
gene transfer can modify the course of the atherogenic cascade by elevating the 
plasma HDL.  Mechanisms of HDL not related to lipid metabolism are: 
(a)  HDL inhibits adhesion and migration of monocytes into the arterial 
 intima 
(b)  Stimulates cell repair and proliferation 
(c)  Preserves endothelium-dependent vascular activity 
(d)  Inhibits growth factor induced VSMC proliferation and 
(e)  Prevents thrombosis. 30 
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Role of CETP in atherosclerosis  
It is a hydrophobic glycoprotein with Molecular Weight of about 70,000 to 
74,000 Da. It is synthesized in many organs of the body apart from the heart and 
induced during the differentiation of monocytes into macrophages. It is a major 
protein involved in reverse cholesterol transport. It regulates the plasma 
concentrations of HDL cholesterol and the size of HDL particles. 
Clinical significance                                                                                
Persons having deficiency of cholesterol ester transfer protein are known 
to have marked hyper alphalipoproteinemia.31                                                                                             
Enzymes of lipid metabolism 
Lipoprotein lipase and hepatic lipase are the two important enzymes 
involved in lipoprotein metabolism. They belong to the family of neutral lipases. 
These two lipases play important role in the metabolism of triglyceride-rich 
proteins.       
Lipoprotein lipase is intravascular in location and attached to endothelial 
cells. This enzyme is produced chiefly in cardiac and skeletal muscles. These 
organs utilize preferably fatty acids of adipose tissue and mammary glands to 
meet their energy requirement. Lipoprotein lipase hydrolyses lipid fractions on 
chylomicrons and very low density lipoprotein (VLDL) and converts them into 
smaller remnants so that they can be quickly cleared from the circulation.    
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Hepatic lipase is produced and released by hepatocytes and affects HDL 
metabolism. Accumulation of β-VLDL observed in hepatic lipase deficient 
people points that triglyceride-rich particles could be a substrate for this enzyme. 
Studies on hepatic lipase enzyme revealed that it is essential for LDL synthesis 
and its redistribution into HDL fraction. 32 
Defects in these proteins have pathological implication in pathogenesis of 
atheroma. (Lipoprotein lipase produced by macrophages is important in plaque 
formation). Changes in hepatic lipase activity produced by treatment alter the 
density of LDL. This   influences coronary artery disease progression and 
produces a favorable outcome. 33 
Positive correlation exists between post prandial lipemia and the 
progression of coronary artery disease since increased blood level of 
triacylglycerol is achieved from dietary sources. High level of chylomicrons and 
small dense LDL particles with reduced HDL levels occurs after a fatty meal. 
This biochemical profile promotes thrombosis by activating coagulation factor 
VII and platelet activator inhibitor. 34 
LDL-Cholesterol  
Sequestration of LDL particles in the vessel wall and its subsequent 
oxidation is considered to be an important event in the early stages of an 
atherosclerotic lesion.  
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1. OxLDL  particles enhance the recruitment and retention of monocytes 
and lymphocytes  
2. They promote conversion of monocytes into macrophages 
3. Increase the production of various growth factors and cytokines.  
The toxic effect of oxLDL has been demonstrated in cultured Vascular 
Smooth Muscle Cells and fibroblasts. Animal studies show that oxLDL induces 
the release of FGF-1 in a concentration-dependent manner. This effect has good 
correlation with the extent of oxidative modification of oxLDL. 35 During the 
oxidative process of LDL particles, the Apo lipoproteins, cholesterol and the 
esterified unsaturated fatty acids in phospholipids or cholesterol esters are  
modified.                  
                      LDL MODIFICATION AND OXIDATION 
15-LIPO OXYGENASE  
In reticulocytes of mammals, eosinophils and certain other cell types, 15-
LOX are expressed at high concentrations. But they are not expressed in 
peripheral monocytes or normal vessel wall. However, the expression of 15-LOX 
can be induced in human monocytes in the presence of interleukin IL-4&IL-13. 
Studies with transgenic mice with a knockout for the LOX gene have shown a 
reduction in the incidence of atherosclerosis. In vitro, LOX modifies LDL in 
such a way that it can be taken up by macrophages.  
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So, overexpression of 15-LOX in macrophages and monocytes increases 
capability to metabolize LDL particles to counter the deleterious effects of 
hypercholesterolemia. The available data suggest that overexpression of 15-LOX 
is to afford protection against atherosclerosis. Accordingly, it has been concluded 
that 15-LOX is a complex enzyme with proatherogenic and antiatherogenic 
effects.36 LDL is formed in the early stages of atherosclerosis, while oxLDL is 
formed in the later  stages.37 Although  LDL binds to LDL receptor and oxLDL 
binds to scavenger receptor, the vascular effects of minimally modified LDL and 
oxLDL are similar. Both of them  
1.  Activate endothelial cells, SMC and monocytes.  
2.  Facilitate vasoconstriction, thrombosis and platelet aggregation 
associated with the activation of intracellular protein kinases and 
transcription factors such as NFκB or activator protein-1.                  
3.  Causes expression of cellular adhesion molecules on endothelial cells 
and monocytes  and the synthesis of monocyte chemo attractant 
protein-1  (MCP-1), cytokines and growth factors particularly  platelet-
derived growth factor (PDGF) and procoagulant factors such  as 
plasminogen activator inhibitor-I .                                                                                     
4.   Induces a vasoconstrictor state by reducing the formation of the 
endothelium-derived vasodilators, NO and prostaglandin while 
enhancing the production of the vasoconstrictor endothelin-1 (ET-1). 
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In the sub endothelial space, the uptake of oxLDL by monocyte-derived 
macrophages reduces macrophage migration and leads to the formation of foam 
cells, the hallmark of atherosclerotic lesions. OxLDL is chemotactic for 
monocytes and T-cells. Furthermore, monocytes or macrophages present 
antigenic epitopes of oxLDL to B-cells, inducing the formation of antibodies to 
oxLDL and an immune reaction towards deposited oxLDL.37 Endothelial cells 
mediate the uptake of oxLDL by a recently cloned lectin-like oxLDL receptor-1, 
which is also involved in mediating endothelial phagocytosis of aged and 
apoptotic cells. The production of lectin-like oxLDL  receptor-1 in endothelial 
cells is induced by tissue necrosis factor-alpha (TNF-α), ET-1, shear stress, tissue 
growth factor-beta (TGF-β) and angiotensin II, which accelerates foam cell 
formation by increased uptake in endothelial cells and macrophages .38 
Lipid peroxidation by ROS 
In vivo and in vitro oxidative decomposition of omega-3 and omega-6 
polyunsaturated fatty acids of membrane phospholipids by ROS results in lipid 
peroxidation.  Beta-cleavage reaction of lipid hydro peroxides  leads to the 
formation of aldehydic end products including malonyl dialdehyde, 4-hydroxy-
2,3-nonenal and other 4-hydroxy-2,3 alkenals. These lipid metabolites are 
proposed as putative and ultimate toxic messengers. They are potential mediators 
of oxidative stress injury at a molecular level. These metabolites have been 
demonstrated in the sub endothelial space of human aortas. 35 Conversion of 
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polyenoic fatty acids to  hydroperoxy derivatives by lipid peroxidizing enzymes 
is significant step  in atheroma formation.  
ROLES OF ENDOTHELIUM 
 Vascular endothelium is located   between the blood and the vessel wall 
and functions as an endocrine organ. 39, 40 It plays key role in atherosclerosis.  
Functions of endothelium 
1.  It regulates vascular tone, forms NO, Prostacyclins and Endothelins (ETs.) 
2.  It also maintains the composition of sub endothelial matrix. 
3.  It has an important role in proliferation of SMC, coagulation, fibrinolysis, 
permeability of lipoproteins and plasma proteins, and adhesion and 
migration of blood cells.     
Causes of endothelial injury and dysfunction                                                     
1. Turbulent flow of the blood and stretching of the blood vessels causes 
stress and predispose the endothelium to early development of 
atherosclerosis. 41,42,43 
2. Most of damages to the endothelium are due to ROS produced by many 
risk factors such as cigarette smoking, stress, anaerobic metabolism and 
radiation.  
3. Advanced Glycation End Products (AGEP) triggers   oxidative stress 
through generation of ROS in diabetes mellitus and chronic uremia.44 The 
AGEP peptides activates  inflammatory cytokines and enhances Apo 
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lipoprotein B modification, which leads to  increased uptake of LDL 
through the macrophage scavenger receptor (MSR) pathway.  
Damaged or excessively activated endothelial cells secrete   ET-1and 
factors affecting the differentiation and growth of VSMC. These exert a 
chemotactic action on leukocytes and platelets, and induce the expression of 
specific surface adhesion molecules (selectins, integrins and the supergene family 
of immunoglobulins) that interact with ligands on the surface of leukocytes and 
platelets.  
Functions of  ET-1  
 It is a Vasoconstrictor   
 Has mitogenic activity on SMC  
Both mechanisms results in the synthesis and release of free radicals and 
inflammatory cytokines into the circulation. 45 At the sites of injury or 
inflammation, pro inflammatory cytokines such as IL-1 and TNF-α promote 
leukocyte adhesion and activation. They also generate activators of neutrophils, 
such as granulocyte macrophage colony stimulating factor, plasminogen-
activating factor and IL-8.  
Role of Nitrous Oxide 
Current studies support two pathways for the endothelial isoform of NOS 
(eNOS) in atherogenesis.46 Under normal conditions tetra hydro biopterin, an 
antiatherogenic molecule in tissue, regulates eNOS activity to activate NO 
production. However, in hypertension, hypercholesterolemia, smoking, and 
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diabetes mellitus increased oxidative stress oxidizes BH4, leading to BH4 
deficiency. Lower BH4 levels in tissue induces the uncoupling of NOS and 
superoxide, causing endothelial-cell damage.47 
Other proteins involved in ROS production and atherogenesis are 
Chymase, Angiotensin II and Cathepsins. 
Roles of Immune-Mediator Regulation 
Following cells are involved in the inflammatory part of atherosclerosis 
 Macrophages 
 Dendritic cells 
 T cells 
ROS IN ATHEROSCLEROSIS 
ROS production causes oxidation of LDL in two mechanisms. 
1. Extracellular - mediated by action of angiotensin II  on macrophages and 
endothelial cells and   stimulation of endothelial cells by TNF-α and other 
cytokines.                                                                             
2. Intracellular - ROS production in the vascular smooth muscle cells occurs 
through the membrane-bound NAD(P)H oxidases, xanthine oxidase and 
uncoupled NO synthase. Angiotensin II is a powerful inducer of 
NAD(P)H oxidase and can stimulate the production of ROS eightfold in 
the VSMC. Intracellular ROS can serve as second messengers following 
hormonal stimuli 48,49 and act as intracellular signaling molecules in 
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vascular cells. They mediate phenotypic changes in vascular endothelial 
and smooth muscle cells regarding growth, apoptosis and survival. The 
extent of SMC growth response is determined by the net balance between 
proliferation and apoptosis due to ROS production.  
Enzymes of arachidonic acid metabolism, xanthine oxidoreductase 
microsomal cytochrome P-450, and mitochondrial electron transport are the 
potential sources of ROS. Cytokines, physical forces and local hormones regulate 
the activity of these oxidases. Increased superoxide radical production in 
combination with NO produced by endothelium enhances availability of the 
harmful peroxynitrite. 49  Figure 4. Illustrates pathophysiology of atherosclerosis. 
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particles also penetrate arterial wall. Macrophages digest oxidized LDL particles 
and transform into foam cells which causes the formation of fatty streak. The 
activated macrophages release monocyte chemo attractant protein 1, tumor 
necrosis factor α, and interleukins. These chemo attractants and cytokines 
mediate the process by recruitment of more macrophages and vascular smooth 
muscle cell which produce extracellular matrix components at the site of the 
plaque. Macrophages also release matrix metalloproteinases, which digest the 
extracellular matrix leading to plaque disruption.51 In 99% of cases, it is 
clinically silent.53  
Stability of Plaques and Tendency for Rupture 
The stability of atherosclerotic plaques is variable. Characteristics which 
make them vulnerable or high risk are large size, thin fibrous cap, abundance of 
macrophages and T lymphocytes,54,55 a relatively reduced numbers  of smooth 
muscle cells,56  increased levels of matrix metallo proteinases at the  plaque,57,58 
eccentric configuration59,60 increased neo vascularity of plaque and intra plaque 
bleeding.59 Atherosclerotic plaques is  heterogeneous in nature within the same 
individual.60 
Inflammation, the important deciding factor of the “vulnerability” of 
atherosclerotic plaques54, 61 is depended on increased activity of macrophages at 
the site of plaque. This increased activity leads to increased size of the lipid core 
and a thinning of the plaque cap which increase the tendency to rupture. There is 
a positive correlation between increased levels of C-reactive protein (CRP) with 
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the number of plaque ruptures62 and may reflect the activity of these 
macrophages.63 
Plaque Disruption, Thrombosis, and ACS 
Atherosclerosis diminishes vascular lumen and reduces the perfusion of a 
tissue. Thrombus formation or hemorrhage in an atherosclerotic plaque further 
reduces the lumen of the vessel. The thromboembolic phenomenon associated 
with atherosclerosis that occurs due to rupture of unstable plaques is responsible 
for the acute coronary syndromes and unstable angina. 
Non-critical coronary lesions (<50% stenosis in the diameter of the vessel 
by coronary angiographic studies) may be associated with sudden progression to 
severe or total obstruction of coronary arteries and may be responsible for two-
thirds of cases of ACS. 
Tissue factor  and lipid molecular  content of the plaque, the severity of 
the plaque rupture, the degree of inflammation at the site of the atheromatous 
plaque, vascularity of the area, and balance between pro thrombotic and 
antithrombotic  tendencies  are important determinants for the development of  
ACS. 
Among the risk factors of coronary heart disease dyslipidemia in the form 
of increased total or LDL-Cholesterol, reduced HDL-Cholesterol and 
hypertriglyceridemia is the offender next to smoking.  
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Causes of dyslipidemia: 
Congenital  -  familial hyper lipidemias 
Acquired  - high calorie intake,  
  diabetes mellitus,  
  obstructive jaundice,  
  nephrotic syndrome and  
  hypothyroidism. 
Out of these thyroid gland is closely related to lipid metabolism. Thyroid 
gland exerts its actions on both heart and lipid metabolism.  
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     Para follicular cells are present in spaces between follicles and 
scattered among follicular cells. They are also called C cells and secrete 
calcitonin. 68  Figure 6. Shows the histology of normal thyroid gland.                           
SYNTHESIS AND RELEASE OF THYROID HORMONES 
IODINE TRAP  
 Thyroid hormone is synthesized from aromatic amino acid tyrosine. 
Iodination of tyrosine residues of thyroglobulin (Tg) produces thyroxin and 
triiodothyronine. Active transport of Iodide ( I   ̄ ) from extra cellular fluid into 
thyroid gland   through Na/I  (sodium          ̄        - iodide) symport (NIS) is the beginning 
step in thyroid hormone synthesis. After entry, cytoplasmic iodide moves into 
colloid via pendrin, a passive iodide transporting glycoprotein. Thyroglobulin  is 
needed for the bio synthesis of thyroid hormone and account for 75% of total 
glandular protein. TSH is the principal stimulator of Tg synthesis. Thyroid 
transcription factor 1 (TTF1) interacts with Tg promoter to stimulate Tg mRNA 
synthesis.        
OXIDATION OF IODINE    
               In the lacuna, the iodide is oxidized to iodine by Thyro peroxidase 
(TPO) enzyme. Hydrogen peroxide (H₂O₂) serves as the terminal electron 
acceptor forming H₂O₂  ̄. Hydrogen peroxidase is generated by dual oxidases 
(DUOX1and DUOX2) which has domains analogous to the domains found in 
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxido reductases. 
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IODINATION          
 TPO catalyzes mono and di-iodination of tyrosine residues of 
thyroglobulin (Tg) and monoiodotyrosine   (MIT) and diiodotyrosine (DIT) are 
formed.    
COUPLING                                                                                          
 T₃ is formed from one MIT and DIT with the transfer of one mono 
iodinated phenolic group to a DIT residue. T₄ is formed from two DIT residues 
with transfer of one di-iodinated phenolic group to another DIT residue.  
STORAGE 
 At this stage both T₃ and T₄ are bound to thyroglobulin (Tg) which 
remains in the colloid providing reservoir of thyroid hormone.  
RELEASE 
 On stimulation by TSH the apical pole of the follicular cells releases 
colloid into a vesicle by pinocytosis. Digestion of intra vesicular colloid 
(containing thyroglobulin) occurs in follicular cells after fusion of phagosome 
body with the primary lysosome.  A secondary lysosome is formed by union of 
endocytosed Tg with primary lysosome. Digestion of Tg and release of T₃, T₄, 
MIT, DIT and amino acids occurs. Since T₃ and T₄ are lipophilic they diffuse 
through lysosomal membrane, cross the follicular cells and enter into capillaries.  
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These receptor proteins in turn  binds with thyroid hormone response elements 
(TREs) in the promoter regions of positively regulated genes  and mediates the 
induction of transcription.73 Thyroid hormones nuclear receptors  belong to the 
superfamily of steroid hormone receptors. TRs can bind to TREs in the absence 
as well as in the presence of ligand. TRs bind to TREs as homodimers or 
heterodimers with one of the three isoforms of retinoid X receptor (RXRα, 
RXRβ, or RXRγ). On binding to T₃, TRs induce transcription, and in the absence 
of T₃ they repress transcription.74 Negatively regulated cardiac genes such as  β-
myosin heavy chain and phospholamban are induced in the absence of T₃ and 
repressed in the presence of T₃.75  
    Thyroid hormone effects on the cardiac myocyte are intimately associated with 
cardiac function via regulation of the expression of key structural and regulatory 
genes. The myosin heavy chain genes encode the 2 contractile protein isoforms 
of the thick filament in the cardiac myocyte. The sarcoplasmic reticulum                  
Ca2+-ATPase and its inhibitor, phospho lamban, regulate intracellular calcium 
cycling. Together they are largely responsible for enhanced contractile function 
and diastolic relaxation in the heart.76 The β-adrenergic receptors and sodium 
potassium ATPase are also under T₃ regulation. Thyroid hormone also exerts 
thyroid hormone response elements (TREs) in the promoter regions of positively 
regulated genes. 
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Extra nuclear actions  
The extra nuclear effects of T₃ on the cardiac muscle and on the systemic 
vessels do  not involve TRE-mediated transcriptional events.77These effects  are  
rapid and mediated  through changes in characteristics of  membrane ion 
channels for sodium, potassium, and calcium, effects on actin polymerization, 
adenine nucleotide translocator-1 in the mitochondrial membrane and many 
intracellular signaling pathways  in the cardiac and  vascular smooth muscle cells 
(VSM)78. Ultimately the combined nuclear and extra nuclear actions T₃ regulates 
cardiac function and   cardiovascular hemodynamics.  
THYROID HORMONES AND LIPID METABOLISM 
The activity of the enzymes involved in the metabolism of lipoproteins 
and reverse cholesterol transport, such as hepatic lipase (HL), lipoprotein lipase 
(LPL), Cholesteryl-Esters Transfer Protein (CETP) and Lecithin-Cholesterol 
Acyl transferase (LCAT) is increased by thyroid hormones. 
3-Hydroxy-3-Methyl-Glutaryl Coenzyme A Reductase (HMGCR), the 
rate-limiting enzyme in cholesterol synthesis is regulated by thyroid hormones 
like many hormones, such as insulin. In a state of hypothyroidism, HMGCR 
mRNA levels are diminished and therapy with thyroxin restores it to normal 
level. Thyroid hormone stimulates HMGCR transcription and increases its 
stability. 
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Stimulation of HMGCR by thyroid hormones occurs via SREBP-2 (Sterol 
Regulatory Element Binding Protein-2), a cholesterol sensing factor. Low 
Density Lipoprotein Cholesterol Receptor (LDL-R) and ATP-Binding Cassette 
Transporters (ABCA1 and ABCG5/8). 
When intracellular cholesterol is reduced, thyroid hormone stimulates the 
transcription of SREBP2 gene and leads to increasing SREBP-2-mediated 
HMGCR gene transcription. Thyroid hormone-mediated LDL-R and 
BCA1/ABGG5/8 expression plays a major pathway for hepatic cholesterol 
clearance. It also diminishes the cholesterol through augmenting cholesterol 
clearance pathway. Cholesterol 7-hydroxylase (CYP7A1) is  also regulated by 
thyroid hormones. 
Effects on triglyceride 
At transcription level, ANGPTL3 is negatively regulated by thyroid 
hormone, which is mediated by TRβ. Expression of this inhibitor causes 
increased TGL and total cholesterol. Thyroid hormone influences the 
maintenance of triglyceride levels by regulating APOA5gene transcription. 
Apo A5 regulates TGL level by stimulating Lipoprotein Lipase mediated 
hydrolysis of triglycerides and inhibiting hepatic VLDL-TGL formation.80 
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PHYSIOLOGY OF AGING THYROID GLAND 
 Morphological studies done on thyroid gland revealed that degenerative 
processes occur in thyroid epithelium which results in  flattening, reduction in the 
size of thyroid follicles and  proliferation of lymphoid and  fibrous connective 
tissue. 
Consequences of these changes are reduction of   the size of the thyroid 
gland and reduced Iodine uptake. In persons over 80 years the Iodine uptake falls 
by 40% in comparison with 30 years old persons. The daily thyroxin production 
is decreased per 20 μg. Conversely, the metabolism of thyroid hormones slow 
down due to the reduction in the activity of 5’ Deiodinase-I which results in 
prolongation of the half-life of T₄  from 8 to 9.3 days without alteration in the 
serum T₄ concentration  over time. The daily synthesis of T₃ reduces per 20 μg in 
males and 10 μg in females, and the serum concentration of T₃ in aged persons is 
reduced significantly. Studies done to evaluate hypothalamic-pituitary-thyroid 
axis exhibited various  patterns of pituitary function: its preserved or reduced 
ability to secrete TSH following different stimuli.81 
EUTHROID SICK SYNDROME 
Definition      
Abnormal levels of thyroid hormones, without clinical evidence of thyroid 
or pituitary gland disorder, are commonly seen in many systemic non thyroidal 
illnesses.  The name "euthyroid sick syndrome" is used to describe  abnormalities 
in thyroid function tests. The incidence may be 70%.Thyroid hormone changes 
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do not indicate thyroid disease. It is a response to the underlying illness, as these 
changes  disappear on  recovery from underlying illness. It is better called as 
"Non thyroidal illness syndrome" 
 Importance of knowledge of this response: 
(a)  Abnormal thyroid profile may  mimic or mask  intrinsic thyroid disease. 
(b) The hormonal alteration in euthyroid sick syndrome represents an adaptive 
response to critical illness, where thyroxin is not helpful.  
(c) The severity and nature of changes in thyroid profile  have implications to 
assess the prognosis.  
Patterns of Euthyroid Sick Syndrome 
 Four major types are described. 
1. Low T3 Syndrome 
This is the most common abnormality observed in about 70% of the in 
patients.82 Serum FT₃ falls rapidly within 30 min to 24 hours of the onset of the 
causative illness. Levels of fall vary from undetectable to normal, and the mean 
value is approximately 40% of the normal level. The daily production of T₃ is 
decreased, while its clearance remains unchanged. The decreased conversion of 
thyroxin (T₄) to T₃ results from the inhibition of enzyme 5'-monodeiodinase             
(5'-MDI) activity, which catalyzes the deiodination of T₄ to T₃. Serum total T₄ 
and free T₄ (FT₄) are normal in patients with low T₃ syndrome. Generally serum 
TSH concentration and its response to Thyrotrophin releasing hormone (TRH) 
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are normal. However TSH level may elevate slightly, but returns to normal with 
recovery. 
 The  reverse T₃ (rT₃) is elevated except in renal failure and traumatic 
brain injury. Daily production rate of rT₃ is normal. The increase in the serum rT₃ 
level is mainly due to its reduced metabolic clearance. 
2. Low T₃ and T₄ syndrome 
The low T₃ and T₄	syndrome is seen in critically ill.  30-50% of patients 
have low levels of T₃ and T₄. The total T₄ levels falls over 24-48 hours period. 
Serum TSH concentration is usually low and there will be blunted TRH 
responses. It may be due to impairment of TRH metabolism. TSH level rises with 
recovery, and may be transiently elevated until T₃ and T₄ levels are restored to 
normal. The rT₃ synthesis diminishes due to the decreased availability of its 
precursor T₄, but because of slow degradation rT₃ concentrations are frequently 
increased. 
Several factors may contribute to low T₃ and T₄ levels. 
These include:  
(1) Reduced binding proteins, e.g., Thyroxin binding globulin (TBG), 
albumin and prealbumin especially in chronic liver disease and in renal 
dialysis,  
(2) Abnormal TBG due to altered sialylation 
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(3) Circulating competitive binding inhibitors of T₄ to serum protein, 
including drugs furosemide in high doses, non-esterified fatty acids 
(NEFA) and metabolic products  
(4) Decreased serum TSH, especially in patients treated with dopamine. 
3. High T4 syndrome 
This is very unusual and  seen  1% of sick patients. It is observed in acute 
intermittent porphyria chronic active hepatitis and primary biliary cirrhosis acute 
psychiatric illness and patients on treatment with amiodarone and radio contrast  
usage for diagnostic purpose. 
The serum concentration of FT₄ remains normal. The high serum T₄ level 
is usually the result of increased serum TBG. FT₃ concentration is typically 
decreased. The serum levels of  rT₃ is also increased. This response due to  both 
a high  concentration of TBG and and a reduced  metabolism of rT₃. The serum 
TSH is very low or undetectable, and TRH response is blunted. 
4. Other abnormalities 
Reduced nocturnal TSH surge, unrelated to circulating T4 and T3 levels, 
but probably related to hypothalamus 
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CAUSES OF EUTHYROID SICK SYNDROME 
1. Medical 
Acute myocardial infarction 
Acute and chronic renal failure 
Alcoholic liver disease 
Hepatic cirrhosis 
Malignancy 
Obstructive airway disease 
Diabetic ketoacidosis 
2. Surgical 
Spinal cord injury 
Major trauma 
Severe burns 
During and after cardiopulmonary bypass 
3. Infections 
Viral hepatitis type A 
Sepsis 
Drugs 
Amiodarone 
Glucocorticoids  
Propranolol  
Radiographic contrast agents 
Phenytoin 
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4. Miscellaneous 
Anti-tuberculosis treatment 
Hemodialysis  
Clinical Significance 
  Low T₃ and T₄ level predict increased mortality from liver cirrhosis and 
congestive heart failure, thus indicating poor prognosis. 
          Evidences are pointing the existence of local hypothyroidism at tissue level 
because of low supplies of T₃ and T₄.  Many patients with non-thyroidal illness 
are metabolically euthyroid in spite of the presence of low serum T₃ and T₄. 
Recent studies demonstrated that tissues of patients dying of Non thyroid illness 
contain lower levels of thyroid hormones than tissues of control subjects who die 
suddenly indicating the impending death. In contrast, studies also suggest that in 
Non-thyroid illness there will be increase in T₃ receptor number and binding 
affinity which maintains normal thyroid status in spite of reduced T₃. 
Treatment    
          The majority of patients of euthyroid sick syndrome who are on recovery   
from their critical illness do not require any treatment. Thyroid function tests 
should be followed up. 
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SUB CLNICAL HYPOTHYROIDISM 
DEFINITION   
 It is defined as a serum thyroid stimulating hormone (TSH) above the 
defined upper limit of the reference range, with a serum free thyroxin (T₄) within 
the reference range. 83 
          Criteria for the diagnosis of sub clinical hypothyroidism 
1.  Other causes of raised TSH level, pre-existing thyroid illness and patients 
on Thyroxin treatment need to be excluded.  
2.  The reference limits for TSH should be standardized.  
3.  Methods used for the TSH assay should have a high functional sensitivity  
(at least 0.02 mU/L) 
 The panel of ATA/AACE concluded that range of 0.45-4.5 mIU/L should 
ultimately be adopted. 
Epidemiology	of	Subclinical	Hypothyroidism 
 An attempt to address the contentious issues of subclinical thyroid disease 
in a non-biased and systematic way was undertaken recently by efforts of the 
American  Endocrine Society, the American Thyroid Association (ATA) and the 
American Association of Clinical Endocrinologists (AACE). These societies             
co-sponsored a Consensus Development Conference in 2002 and contracted an 
independent consulting firm to review and summarize existing published 
evidences.  The reports of epidemiology of this problem are more likely to be 
affected by the reference range of serum TSH which is used to define it. Studies 
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done in different parts of the world reviewed by the panel utilized different 
ranges. In the United States adult population the prevalence rate of subclinical 
hypothyroidism is 4-8.5%. This estimate may increase as age advances and 
differs between ethnic groups. Data of less consistency is available among males. 
The progression rate of SCH to overt or clinical hypothyroidism is approximately                
2-5% per year. It is proportional to baseline serum TSH concentration and is 
more in individuals with anti-thyroid antibodies. Despite the impact of thyroid 
antibody positivity on the epidemiology of subclinical hypothyroidism, the panel 
did not advise the use of anti-thyroid peroxidase (TPO) antibodies. This differs 
from recommendations by the Royal College of Physicians (RCP), AACE, ATA 
and Australian thyroidologists. 
Studies about the consequences of subclinical hypothyroidism 
 In general there was insufficient or no evidence to support an association 
between subclinical hypothyroidism and clinical conditions. The exception was 
dyslipidemia, particularly in patients with a TSH >10 mU/L. Some studies found 
T₄ replacement can improve dyslipidemia. But it is not confirmed by other 
studies. 
 The panel concluded that clinically significant relationship between 
subclinical hypothyroidism and adverse cardiac events or cardiac dysfunction 
was insufficient. Only a single large cross-sectional study gave the conclusion 
that subclinical hypothyroidism was a risk factor for atherosclerosis and 
myocardial infarction. 
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 Evidences are insufficient for  neuropsychiatric and systemic hypothyroid 
symptoms in SCH. A large cross-sectional study demonstrated that participants 
with subclinical hypothyroidism had more symptoms than euthyroid individuals, 
but less symptoms than patients with overt hypothyroid participants and 
distinction was not possible between untreated subclinical hypothyroidism and 
undertreated overt hypothyroidism. Other studies have not confirmed this 
association. Randomized control trials which included patients with a TSH less 
than 10 µIU/ml, found no improvement in symptoms.  
           Like many risk factors overt hypothyroidism has an impact on cardio 
vascular events through changes in lipid profile. Even though there are 
conflicting reports regarding effects of subclinical hypothyroidism on lipid 
profile, its progression to overt hypothyroidism is well documented. So, it is 
worth to do thyroid function tests in ACS patients. 
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MATERIALS AND METHODS 
AIMS and OBJECTIVES OF THE STUDY: 
 To know the prevalence of subclinical hypothyroidism in patients with 
acute coronary syndrome.  
 To compare serum lipid profile changes in Euthyroid with Subclinical 
hypothyroid patients in acute coronary syndrome. 
 To correlate the lipid profile changes with subclinical hypothyroidism in 
patients with acute coronary syndrome. 
STUDY DESIGN 
             The study was conducted as a cross sectional study on 100 patients with 
acute coronary syndrome   at Government Mohan Kumaramangalam Medical 
College Hospital, Salem during the period between December 2017 –May 
2018.The patients were admitted at IMCU or ICCU under the supervision of 
cardiology department. Informed consent was obtained from all patients. All 
procedures concerning patients were permitted by the Institutional Ethical 
Committee.  
STUDY POPULATION: 
INCLUSION CRITERIA:  
 100 cases of ACS giving consent irrespective of age, sex, race and clinical 
severity were included. 
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EXCLUSION CRITERIA:  
 
1.  The patients who refused to give consent.  
2.  Those having thyroid disorders.  
3.  Patients known to have neoplasia anywhere in the body, chronic 
kidney disease, obstructive air way disease, chronic liver disease or 
active infection 
4.  Patients taking steroids, amiodarone or lithium and 
5.  Patients for whom iodinated contrast medium was given in the recent 
past. (2 weeks) 
 Two groups were made depending on the characters of chest pain, ECG 
findings and the results of CK-MB level.  
STUDY GROUPS  
Group1. Non ST-Elevation ACS: (Unstable angina/ non STEMI)   
 Cases with pain at rest or with minimal exertion lasting   >10 minutes or   
 Severe chest pain of new onset (i.e., within the prior 4-6 weeks); or  
 Pain with a crescendo pattern   (i.e. more prolonged, severe, or frequent 
than before) 
 ECG findings of ST depression / T wave inversion with normal or  
elevated serum CK-MB levels.  
 At the time of presentation, patients with UA and NSTEMI can be 
indistinguishable and therefore are considered together in this guideline. 85 The 
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diagnosis of NSTEMI was established if a patient with the clinical features of UA 
develops evidence of myocardial necrosis, as reflected in elevated CK-MB.85  
Group 2: ST elevation MI  
                Cases with symptoms of myocardial ischemia combined with ST 
elevation in electro cardiogram and elevated CK-MB levels, indicative of 
myocardial necrosis were included in STEMI group.       
       The following investigations were done for all the patients in this study.          
1.  Complete Blood Count     
2.  ECG in all leads     
3.  Creatine Kinase- MB iso enzyme     
4.  Random blood glucose level (Fasting and Post prandial if necessary)  
5. Urea and Creatinine  
6.  Fasting lipid profile – total cholesterol, triglycerides, HDL-
Cholesterol. 
7.  FT₃, FT₄ and TSH assay  
8.  Echocardiography (after stabilizing patients)      
SAMPLE COLLECTION:             
  For this study 4ml of fasting venous blood was collected from each of   
the hundred ACS patients under sterile conditions within 24 hours of admission 
with explicit informed consent.  
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I.  2ml of blood was collected in plain vials. Serum was separated after 
centrifugation at 3000 rpm for 10 minutes and aliquoted into eppendorf 
tubes. They were stored at -20°C and were not thawed until the batch 
was analyzed for FT₃, FT₄ and TSH.  
II.  2ml of blood was collected in another set of plain vials and serum was 
separated after centrifugation at 3000 rpm for 10 minutes. Estimations 
of glucose, urea, creatinine, 
CK-MB, total cholesterol, triglycerides and HDL-Cholesterol were done 
with  ERBA XL-640 auto analyzer. Calibration was done with ERBA – Multical  
ESTIMATION OF GLUCOSE  
Method : Glucose oxidase peroxidase (GOD/POD) (End Point) 
Kit Used : ERBA 
Principle 
                                     Glucose oxidase 
Glucose + O ₂ +H₂O                                     Gluconic acid + H2O 
  
                                         Peroxidase   
H₂O₂ + Phenol + 4AAP                                Quinoneimine dye + H₂O 
 The intensity of pink colored Quinoneimine dye is proportionate to 
glucose concentration and was measured at 505nm. 
Reagent Composition 
Active ingredients 
Glucose oxidase → ≥ 20000U/L 
Peroxidase → 800U/L 
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Phenol → 10 mmol/L 
Tris -Phosphate buffer → 50 mmol/L 
Mutarotase → ≥1000 U/L 
ASSAY PARAMETERS 
Reagent volume      -200μl 
Sample volume       -2μl  
Reaction - increasing 
Reference range 
Fasting glucose  - 70-100mg/dl 
Post prandial glucose - 110-140mg/dl 
ESTIMATION OF BLOOD UREA 
KIT: ERBA  
Method: UV - GLDH 
Principle:  
 The test is performed as a kinetic assay in which the initial rate of the 
reaction is linear for a limited period of time. Urea is hydrolyzed by urease to 
NH3 and CO2. The NH3 produced combines with alpha-keto glutarate and NADH 
in the occurrence of glutamate dehydrogenase and produces glutamate and NAD. 
                             Urease 
Urea + H2O                       2NH₃ + CO₂ 
                                                                            
                                                                 GLDH 
NH₃ + NADH + alpha keto glutarate                                 L- Glutamate + NAD⁺	
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The initial rate of decrease in absorbance is directly proportional to the urea 
concentration in the sample. Absorbance is measured at 340nm. 
Reagents 
Reagent 1. 
Tris buffer – 100mmol/L 
Alpha keto glutarate- 5.49mmol/L 
Reagent 2.  
NADH 
Also contains non –reactive fillers and stabilizers  
Assay Parameters 
Reagent 1             - 160 μl 
Reagent 2             - 40 μl  
Sample volume    -  2 μl  
Reaction              -  decreasing 
Primary wave length for measurement of absorbance – 340nm  
Reference range    15-40mg/dl 
ESTIMATION OF SERUM CREATININE 
Kit used :  ERBA 
METHOD : Modified Jaffe's Method  
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 Principle: Creatinine in alkaline solution reacts with picrate to form an 
orange yellow compound. The color is proportional to the concentration of 
creatinine in the sample when measured at 505nm. 
 
Reagent composition: 
Reagent I: 
Picric acid – 26mmol/L 
Reagent II:  
Sodium hydroxide – 240 mmol/L 
Assay parameter 
Reagent I             -160 μl 
Reagent II            - 40 μl 
Sample volume    - 10 μl 
Reaction – increasing 
Reference range 0.7-1.4mg/dl 
ESTIMATION OF CK-MB 
KIT-ERBA 
METHOD-KINETIC 
PRINCIPLE  
 Specific antibodies against CK-M inhibit the complete CKMM activity 
and the CK-M subunit of CKMB. Only CK-B activity is measured.                                           
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                                         CKBB / CKMB 
Creatine phosphate +ADP                            Creatine + ATP  
    
                           
                                            Hexokinase 
    ATP +   Glucose                                       Glucose-6-phosphate + ADP  
                                                                       
                                                                  
                                    
                                        Glucose 6 phosphate dehydrogenase 
Glucose-6-phosphate + NADP                                            Gluconate-6-P+NADPH+ H⁺    
REAGENT COMPOSITION 
R1 
Imidazole buffer, pH 6.1       -125 mmol/l 
Glucose                                  -25 mmol/l 
Magnesium acetate                -12.5 mmol/l 
EDTA                                     -2 mmol/l 
N-acetyl-L-cysteine                -25 mmol/l 
NADP                                     -2.4 mmol/l 
Hexokinase                             > 6.8 U/ml 
Anti-CK antibodies (goat) blocking capacity up to 2000 U/l CK-MM 
R2 
Imidazole buffer, pH 8.9;         125 mmol/l 
ADP ;                                       15.2 mmol/l 
Creatine phosphate                    250 mmol/l 
AMP                                           25 mmol/l 
Diadenosine pentaphosphate     103 μmol/l 
     
59 
D-glucose-6-phosphate-dehydrogenase > 8.8 U/ml 
 The rate of absorbance change at 340 nm is directly proportional to half of 
CK-MB activity (B subunit activity).  
ASSAY PARAMETER   
Sample volume - 8 μl 
Reagent 1  - 160 μl 
Reagent 2  - 40 μl 
Assay type – Rate –A 
Reference range 
 Less than 25 IU/L at  the temperature of 37  C 
 CK-MB activity ranging between 6% and 25 % of the total CK activity 
ESTIMATION OF CHOLESTEROL 
KIT- ERBA 
METHOD – 1point 
Principle.                               
                            Cholesterol Esterase                       
Cholesterol ester                                   Cholesterol + Fatty acids 
                        
                           Cholesterol Oxidase 
Cholesterol + O₂                                 Cholest-4-en-3-one + H₂O₂ 
                                                               
                                                                Peroxidase 
2H₂O₂ + Phenol + 4Amino antipyrin                              Quinoneimine Dye + 4H₂O                       
                                                                                            (Chromophore) 
The Absorbance is proportional  to Quinoe imine dye which may be measured at 
505nm. 
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REAGENT COMPOSITION 
Good‘s Buffer -50 mmol/l 
Phenol 5 - mmol/l 
4-aminoantipyrine -0.3 mmol/l 
Cholesterol esterase ≥ 200 U/l 
Cholesterol oxidase ≥ 50 U/l 
Peroxidase ≥ 3 kU/l 
Assay parameter 
Reagent 1 - 200 μl 
Sample volume - 2 μl 
Reaction –increasing 
Reference range  
Adult  
Desirable   < 200 mg/dl 
Borderline high 200-239mg/dl 
High   ˃ 239 mg/dl 
Child 
Desirable   < 170mg/dl 
Borderline 170-199mg/dl 
High ˃ 199 mg/dl 
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ESTIMATION OF TRIGLYCERIDES.  
KIT- ERBA 
Method – Glycerol -3-phosphate oxidase method 
PRINCIPLE  
 The following s reactions occur in the assay system                                                             
                                                  Lipoprotein Lipase 
Triglycerides + H₂O                                                     Glycerol + Free Fatty acids           
                            
                                                  Glycerol Kinase 
Glycerol + ATP                                                       Glycerol-3-phosphate + ADP 
 
                                        Glycerol-3-Phosphate Oxidase 
Glycerol-3-phosphate + O₂                                                DAP + H₂O₂	
 
                                                        Peroxidase 
H₂O₂ + 4AAP + TOOS                                                    Quinoneimine + H₂O 
                      (Coloring dye)                                 
 Absorbance of this dye is proportional to the concentration present in the 
sample. 
 
REAGENT COMPOSITION 
R1 
PIPES buffer  (pH 7.0) 50 mmol/l 
TOOS      0.48 mmol/l 
Mg ⁺⁺  60 mmol/l 
ATP 2.85 mmol/l 
Glycerol kinase ≥ 1.5 U/l 
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Glycerol-3-phosphate-Oxidase ≥ 6 U/l 
R2 
Peroxidase ≥ 15  U/l 
Lipoprotein lipase ≥ 25U/l 
4-Aminoantipyrine 0.5 mmol / l 
ASSAY PROCEDURE 
Wavelength 500 (546) nm 
Reaction – increasing 
Reagent 1 160 μl 
Reagent 2   40 μl 
Sample volume 2 μl 
REFERENCE RANGE          
Preferable range – less than 150mg/dl                                           
ESTIMATION OF HDL-CHOLESTEROL  
KIT - ERBA 
PRINCIPLE 
 Modified polyvinyl sulfonic acid (PVS) and poly ethylene glycol-methyl 
ether (PEGME) coupled classic precipitation method with the improvements  
LDL, VLDL and chylomicron (CM) react with PVS and PEGME and the 
reaction causes inaccessibility of LDL, VLDL and CM by cholesterol oxidase 
(CHOD) and cholesterol esterase (CHER).The enzymes selectively react with 
HDL to produce H₂O₂ which is detected through a Trinder reaction.                                            
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                                            PVS, PEGME 
 HDL + LDL + VLDL + CM                     HDL + (LDL + VLDL + CM) • PVS / PEGME 
                                          
        Cholesterol oxidase, Esterase 
HDL                                                  Fatty Acid + H₂O ₂ 
                                        
                                        Peroxidase 
2H₂O₂+4-AA+TOD                                           Quinone + 5 H₂O 
 
REAGENT COMPOSITION 
R1 MES buffer (pH 6.5)    - 6.5 mmol/l 
 TODB N, N-Bis(4-sulfobutyl)-3-methylaniline - 3 mmol/l 
 Polyvinyl sulfonic acid -50 mg/l 
 Polyethylene-glycol-methyl ester -30 ml/l 
 MgCl₂ - 2 mmol/l 
R2      MES buffer (pH 6.5) -50 mmol/l 
           Cholesterol esterase - 5 kU/l 
           Cholesterol oxidase- 20 kU/l 
           Peroxidase 5 kU/l 
           4-aminoantipyrine 0.9 g/l 
           Detergent 0.5 % 
R3 CAL          
 HDL/LDL Calibrator      
ASSAY PROCEDURE 
Wavelength: 600/700 nm  
Reaction- increasing 
Assay type – 2 - point. 
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Reagent-1    180 μl 
Reagent-2     60 μl 
Sample volume   2 μl 
Reference range 
Adult male- 35.3-79.5mg/dl 
Adult female 42- 88mg/dl 
Thyroid profile Assay 
INSTUMENTS -ROBONIK Elisa Reader and Washer  
Free T₃ Assay   
KIT - RecombiLISA 
TEST PRINCIPLE  
It is a competitive solid-phase enzyme-linked immunosorbent assay for 
the quantitative measurement of FT₃in human serum.  
Materials and reagents needed 
Anti-FT₃Ab coated micro wells 
FT₃ Calibrators (0, 1.5, 4.5,9,18,32 pgs. /ml) 
HRP conjugates 
Wash buffer 
TMB substrate 
Stop solution 
ELISA working sheet 
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Procedure 
1.  Desired number of micro wells were removed and secured in the micro 
plate frame.    
 2.  50μl of FT₃ calibrators and patient specimens were added into the 
assigned wells. 
 3. 100μl of HRP-T3 was dispensed in each well except the Blank Wells. 
 4.  The micro plate gently was rocked for 20 seconds, and then covered 
with the plate with micro plate sealer.  
5.  The wells were incubated at room temperature (20-28°C) for 60 
minutes.  
6. Wash Step (automated washing): Automatic plate washer was calibrated 
to ensure efficient washing. Each well was filled with 350μl working 
wash buffer and soaked for 20-30 seconds.  All wells were aspirated 
completely. Repeated for 4 more times.  
7.  100 μl of TMB Substrate was added into each well, including the Blank 
Well. Gentle rocking of the micro plate for 20 seconds to ensure 
thorough mixing was done.  
8.  Micro plate was incubated at room temperature (20-28°C) in dark for 15 
minutes.  
9.   100 μl of Stop Solution was added into each well to stop the reaction, 
including the Blank Well. Gentle mixing for 20 seconds was done.  It is 
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important to make sure that all the blue color changes completely to a 
yellow color.  
10. Micro plate reader was set for  wavelength at 450 nm. The absorbance 
(OD) of each well against the Blank Well within 15 minutes after 
adding Stop Solution was measured.  
Free T₄ assay 
KIT – RecombiLISA 
Materials and reagents needed 
Anti-FT₄ Ab coated micro wells 
FT₄ Calibrators (0,0.62,1.2,1.8,3.8,7.5 ng /dl) 
HRP conjugates 
Wash buffer 
TMB substrate 
Stop solution 
ELISA working sheet 
TEST PRINCIPLE  
It is a competitive solid-phase enzyme-linked immunosorbent assay for 
the quantitative measurement of FT3 in human serum.  
Procedure 
1.  Desired number of micro wells were removed and secured in the micro 
plate frame.  
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2.  50μL of fT4 calibrators and patient specimens were added into the 
assigned wells.  
3.  100μL of HRP-T4 Conjugate was dispensed into each well except the 
Blank Wells.  
4.  Micro plate was rocked gently for 20 seconds, and then covered with a 
sealer.  
5.  The wells were incubated at room temperature (20-28°C) for 60 
minutes.  
6.  Wash Step (performed with automated washing):  
 Automated washing: Automatic plate washer must be calibrated to 
ensure efficient washing. Each well should be filled with 350μL diluted 
wash buffer and soak for 20-30 seconds. All wells should be aspirated 
completely repeated 4 more times.  
7.  100μL of TMB Substrate was added into each well, including the Blank 
Well.  
  The micro plate was rocked gently for 20 seconds to ensure thorough 
mixing.  
8.  Incubation was done at room temperature (20-28°C) in dark for 15 
minutes.  
9.  100μl of Stop Solution was added to each well including the Blank 
Well. Gentle mixing was done for 20 seconds. It is important to make 
sure that all the blue color changes completely to a yellow color.  
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10. Micro plate reader was set at wavelength at 450 nm. The absorbance (OD) of 
each well against the Blank well was measured within 15 minutes after adding 
Stop Solution.  
TSH ASSAY 
   
 KIT – RecombiLISA   
PRINCIPLE 
 Solid phase enzyme linked immune sorbent assay based on sandwich 
technique.  
PROCEDURE 
 The test samples and HRP-anti-TSH conjugates are incubated 
simultaneously with the coated micro wells. The TSH in serum reacts to the anti- 
β TSH antibody coated on the micro well surface as well as the HRP-anti-TSH 
conjugates, forming an antibody sandwich immune complex. Unbound 
conjugates are then removed by washing. The presence of the conjugate complex 
is identified by development of a blue color upon additional incubation with 
substrate. The reaction is terminated with Stop Solution and the absorbance 
determined using a spectrophotometer at 450/620-690 nm.  
 A standard curve is generated by plotting the absorbance at 450/620-690 
nm wavelength versus the respective TSH concentration for each standard. The 
concentration of TSH in the serum is calculated from the curve. 
1.   Desired quantity of strips were taken out and positioned in the micro 
plate frame.   
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2.  50 μl of the TSH Standards and patient specimen were added in the 
assigned wells.  
3.  50 μl of HRP-anti-TSH conjugates was added into each the well except 
the Blank Wells.  
4.  Gentle Rocking of the micro plate for 30 seconds covering the plate 
with a micro plate sealer was done.  
5.  Incubation of the wells at 37ºC for 60 minutes was done. 
 6.  Careful removal of the the incubation mixture by emptying the solution 
into a waste container, filling each well with diluted Wash Buffer and 
shaking for 20-30 seconds were done. Washing was done 4 more times.  
To remove residual liquid tapping on absorbent paper was done.  
7.  100 μl of TMB Substrate was added into each well, including the Blank 
Well and gentle mixing was doe.  
8.  Incubation in dark room at room temperature (20-25ºC) for 20 minutes 
was done.  
9.   100 μl of Stop Solution was added to each well gentle mixing was done 
for 30 seconds.  
 It is important to ensure that all the blue color completely changes to a 
color yellow.  
10. Micro plate reader was set for the wavelength at 450 nm and the 
absorbance (OD) of each well against the Blank Well was measured 
within 15 minutes after adding Stop solution.  
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 The reference ranges of these tests made in the department of 
biochemistry at Government mohan kumaramangalam medical college hospital 
are shown in table 2. below:  
TABLE 2. Reference  ranges for the biochemical parameters estimated in 
this study. 
Biochemical Test Reference Range 
Fasting blood glucose 70-100mg/dl 
Post prandial glucose 110-140mg/dl 
Urea 15-40mg/dl 
Creatinine 0.7-1.4mg/dl 
CK-MB 0-25 IU/L 
Cholesterol Less than 200mg/dl 
Triglycerides Less than 150mg/dl 
HDL-C 30-60mg/dl 
Free T3 1.16 - 4.34 pg/dl 
Free T4 0.58-2 ng/ml 
TSH 0.4 - 5 μIU/ml 
LDL-Cholesterol  calculated by 
Friedewald equation 84 
Less than 130mg/dl 
 
 
     
71 
STATISTICAL ANALYSIS 
 
 Graph pad prism version 7 was used for statistical analysis.   
 P value less than 0.05 was considered as statistically significant.  
 Data of age and fasting blood glucose level of whole study population 
were compared with their TSH level.  
 Comparisons between data of TSH and lipid profiles of euthyroid 
group and subclinical hypothyroid group were done with paired t test.  
 Correlation between data of lipid and thyroid profile of subclinical 
hypothyroid patients and euthyroid patients was made with Pearson’s 
correlation analysis.  
 Categorical data (different age groups, gender, clinical severity types) 
were analyzed with Chi square or fisher’s exact test  
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RESULTS 
The Mean age of the study population was 57.05 ± 11.15years                          
(range 34 – 95 years).  72 (72%) were males and 28 (28%) were females. 
61patients (61%) had presented with STEMI and 39 patients (39%) presented 
with Non ST Elevation ACS (NSTEMI and UA). These data are showed in  
Table 3. 
Table 3: Baseline characteristics and presentation of the study population. 
                                     Variables Total patients - 100 
No of 
patients 
Percentage
Age Mean ± SD     
57.05 ± 11.15 
 
Range   34- 95 years 
60 yrs. and 
above 
44          44 
40-59 yrs. 48          48 
Less than 40 
yrs. 
 8            8 
Gender  Male  72           72 
Female  28           28 
ACS 
type 
STEMI 61           61 
Non ST Elevation ACS 39           39 
   
Out of 100 patients included in this study 44 were in the age of 60 years 
and above; 48 were between 40 -59 years of age; 8 patients were below the age 
of 40 years.  It is shown in figure 11.                                                                                                  
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Figure 14. Distribution of Risk factor in ACS patients 
 
Gender, age and clinical severity in SCH patients  
The prevalence  of Sub clinical hyothyroidism in patients aged 60 and 
above was 4.54% and 8.93% in patients aged below 60 years.There was no 
statistical difference in prevalence of subclinical hypothyroidism between these 
groups. Regarding the gender, prevalence of SCH in males was 5.56% and  
10.71% in females.There was no statistical difference in males and females. 
The prevalence of SCH in STEMI patients was 8.2%.  It was 5.13%  in 
Non ST Elevation ACS. There was no statistical difference in these clinical 
severity groups.  It is shown in Table 5. 
         
  
0% 5% 10% 15% 20% 25% 30% 35% 40% 45%
Diabetes
Hypertension
smoking
Family history of premature CAHD
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Table 5.   Age, gender and severity distribution of SCH Patients 
Variable Age Total No 
No of 
SCH 
Percentag
e P value 
 
Age 
   60 and above 44 2 4.54%   
     0.461 
 
       ns 
    Less than 60 56 5 8.93%  
 
Gender 
    Males 72 4 5.56%   
   0.3963 
 
     ns 
    Females 28 3 10.71% 
 
ACS 
Type 
    STEMI 61 5 8.2%  
     0.7021 
 
      ns 
       Non 
ST Elevation 
      ACS  
 
 
39 
 
2 
 
5.13%   
 
Lipid profile of  patients with  different thyroid status 
Patients with euthyroid profile had hypercholesterolemia in 33.3%, 
hypertriglyceridemia in 34%, increased LDL-C level in 24.6% and lowered HDL 
in 26.1%. 
In subclinical hypothyroid patients hypercholesterolemia was seen in 
14.3% and hypertriglyceridemia in 42.9%.  High level of LDL-C level was seen 
in 14.3% and  HDL-C level was decreased in 28.6%of SCH patients.  Tables -
6&7 and Figures 15&16 Illustrates the lipid profile abnormalities in different 
thyroid states in the whole study population.  
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                       Table 6. Lipid profile changes in different thyroid states 
Thyroid state ACS 
type & No 
    High TC    High TGL High LDL - C Low HDL - C 
Gender No Gender No Gender No Gender No 
Euthyroidism 
   Total- 69 
STEMI 
   (38) 
M F  
 
 
 
23 
M F  
 
 
 
24 
M F  
 
 
 
17 
M F  
 
 
 
18 
 
13 7 13 2 10 1 8 1 
Non STE 
   ACS 
   (31) 
2 1 4 5 4 2 8 1 
 Subclinical 
Hypothyroidism 
  Total - 7 
STEMI 
    (5) 
1 -  
 
1 
1 1  
 
3 
1 -  
 
1 
- 2  
 
2 
Non STE 
   ACS 
    (2) 
- - - 1 - - - - 
Subclinical 
hyper- 
thyroidism 
Total- 4 
STEMI 
    (3) 
- -  
 
- 
- -  
 
- 
1 -  
 
1 
2 -  
 
2 Non STE 
   ACS 
    (1) 
- - - - - - - - 
Overt  
Hypothyroidism  
Total- 1 
STEMI 
    (1) 
1 
 
- 
 
1 
 
- 
        
- 
 
- 
 
1 
      
- 
 
1 
 
- - - 
 
Table 7.  Lipid profile of ESS and Low FT₄ states of the study population. 
 
Thyroid 
status 
 
ACS type 
High TC High TGL High LDL-C Low HDL-C 
Gender 
M     F 
No Gender 
M     F 
No Gender 
M      F 
No Gender 
M    F 
No 
 
ESS(16) 
STEMI 5 -  
6 
6 -  
10 
3 -  
4 
2 1  
5 NSTE-ACS 1 - 2 2 - 1 - 2 
Low FT₄(3) STEMI - 1 1 - 1 1 - 1 1 1 1 2 
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Thyroid status and lipid profile of the study population 
 Thyroid profile of Euthyroid sick syndrome was observed in 16 patients  
13 of them were males. Eleven of the patients had ST elevation MI.  Two of 
them   presented with non ST elevation ACS. Out of three females, one presented 
with ST elevation MI and others had non ST elevation ACS.  Low FT₄ was 
found in three patients who had presented with ST elevation MI . Two of them 
were females. 
Analysis of numerical data  
Means, standard deviations of age fasting blood glucose, urea, creatinine  
and CK-MB  are given in Table 8. 
Table. 8 Results of baseline investigations of the study population. 
Variable Number Mean Standard deviation 
Age 100 57.05 11.15 
Fasting blood Glucose 100 120.68 27.35 
Urea 100 30.47 9.08 
Creatinine 100 1.03 0.21 
CK-MB 
 
MI 64 247.2 197.4 
UA 36 15.5` 3.75 
 
 Data of age and fasting blood sugar was compared with serum TSH level 
of whole study population. There was Statistical significance. This is shown in 
Table 9. 
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Table 9.  TSH vs. Age and Fasting blood glucose of ACS patients 
ANALYTE VARIABLE NUMBER MEAN SD PAIRED t TEST 
t 
value
df P value Significance 
α ˂ 0.05 
 
 
TSH 
AGE 100 57.05 11.5 44 99 ˂0.0001 YES 
FASTING 
BLOOD 
GLUCOSE 
100 120.68 27.35 42 99 ˂0.0001 YES 
Comparisons were made between data of TSH and TC, TGL, HDL-C and 
Cal-LDL-C in euthyroid patients. There was significant statistical difference.  
Results are shown in table 10. 
TABLE 10. TSH vs. LIPID PROFILE in Euthyroid patients 
ANALYTE VARIABLE  NUMBER MEAN SD  PAIRED t TEST 
 
 
TSH 
 
  
TC 
 
      
      69 
 
 
168.36 
 
 
43.45 
 t 
value 
 df P 
value  
Significance 
α ˂ 0.05 
31.73 68 ˂0.001  YES  
TGL      69 142.4 76.14 15.43 68 ˂0.001  YES 
HDL      69 35.48 12.01 22.7 68 ˂0.001  YES 
Cal-LDL      69 105.02 34.06 25.1 68 ˂0.001  YES 
Comparisons were made between data of TSH and TC, TGL, HDL-C and 
Cal-LDL-C in Subclinical hypothyroid patients. There was significant statistical 
difference.  Results are shown in table 11.  
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Table 11.TSH vs. LIPID PROFILE in SCH patients 
ANALYTE VARIABLES NUMBER MEAN SD PAIRED T TEST 
t value df P value Significance
α ˂ 0.05 
TSH TC 7 153.88 37.98 9.793 6 ˂0.0001 significant 
TGL 7 142.6 48.66 6.835 6 ˂0.0005 significant 
HDL 7 34.91 12.71 6.532 6   0.0006 significant 
C-LDL         7    9.99 33.74 6.01   6   0.0010 significant 
Correlation studies  
 Pearson’s correlation studies were done between data of TSH and HDL-C 
fraction of lipid profile in euthyroid and subclinical hypothyroid patients. There 
is a significant positive correlation between TSH level and HDL-C in euthyroid 
patients; No significant correlation was observed between TSH and HDL-C level 
in subclinical hypothyroid patients.  
The results are shown in table 12 and 13. 
Table 12.Pearson’s correlation of TSH with HDL-C in Euthyroid patients 
ANALYTE  TSH HDL 
 
TSH 
 
Pearson correlation 1 0.28 
Sig (2 tailed)  ˂0.0001 
N 69 69 
 
HDL 
Pearson correlation 0.28 1 
Sig (2 tailed) ˂0.0001  
N 69 69 
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Table 13.Pearson’s correlation of TSH vs. HDL-C in SCH 
ANALYTE  TSH HDL 
 
TSH 
Pearson correlation 1 0.3736 
Sig (2 tailed)  0.1448 
N 7 7 
 
HDL 
Pearson correlation 0.3736 1 
Sig (2 tailed) 0.1448  
N 7 7 
          The TSH levels of SCH patients were correlated with Total cholesterol, 
Triglycerides and Cal- LDL. There was no statistically significant correlation 
found.  XY plot for correlation study is shown in figure 17. Results are shown 
tables 14, 15, 16.                                                                                       
Figure17. Correlation study of TSH level with lipid profile in SCH patients 
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Table 14.Pearson’scorrelation of TSH with TC in SCH patients 
ANALYTE  TSH TC 
 
TSH 
Pearson correlation 1 -0.095 
Sig (2 tailed)  0.839 
N 7 7 
 
TC 
Pearson correlation -0.095 1 
Sig (2 tailed) 0.839  
N 7 7 
 
Table 15.Pearson’s correlation of TSH with TGL in SCH 
ANALYTE  TSH TGL 
 
TSH 
Pearson correlation 1 -0.437 
Sig (2 tailed)  0.327 
N 7 7 
 
TGL 
Pearson correlation -0.437 1 
Sig (2 tailed) 0.327  
N 7 7 
 
Table16.Pearson’s correlation of TSH with C- LDL in SCH 
ANALYTE  TSH C-LDL 
 
TSH 
Pearson correlation 1 -0.202 
Sig (2 tailed)  0.663 
N 7 7 
 
C- LDL 
Pearson correlation -0.202 1 
Sig (2 tailed) 0.663  
N 7 7 
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DISCUSSION 
          Subclinical hypothyroidism is a common form of thyroid disorder and 
usually asymptomatic.  Most of the cases of SCH are diagnosed by screening 
with the support of laboratory methods. It is identified by abnormally elevated   
serum TSH levels with FT₄ and FT₃ concentrations within the reference range. 
Debate has been going on regarding the association of SCH with increased risks 
of altered cardio vascular hemodynamics, adverse cardiac events and lipid 
profile.  
Lipid and Thyroid Profiles of ACS patients 
            On comparing thyroid status and lipid profile, our study showed that ACS 
patients with euthyroid profile had hypercholesterolemia in 33.3%, 
hypertriglyceridemia in 34%, increased LDL-C level in 24.6% and lowered 
HDL-C in 26.1%. Normal lipid profile at the time of presentation was observed 
in 31.9% of euthyroid ACS patients.  
            In the subclinical hypothyroid status, hypercholesterolemia occurred in 
14.3% and hypertriglyceridemia in 42.9%.  LDL-C level was increased in 14.3% 
and HDL-C level was decreased in 28.6% of SCH patients. Normal lipid profile 
was observed in 28.6% of SCH patients. 
           Results of our study revealed that patients with subclinical 
hypothyroidism have changes in their lipid profile only in HDL-C and 
triglycerides fractions rather than total cholesterol and LDL-C.  
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 Results of our study were inconsistent with the observations of Duntas and 
Wartofsky study in which patients with the thyroid profile of Subclinical 
hypothyroidism had serum lipid profile abnormalities more in Total cholesterol 
and LDL-Cholesterol fractions and also with the results of Colorado study in 
which subclinical hypothyroid patients had more elevated serum total cholesterol 
concentrations than euthyroid individuals.86 However, our results were partially 
concordant with NHANES III cohort study in which higher total cholesterol and 
triglycerides concentrations were observed in subclinical hypothyroid patients. 
Our study showed higher serum triglycerides concentration along with reduced 
HDL-C in subclinical hypothyroidism. Discrepancy between these studies may 
be due to the differences of the study populations, selection criteria, age, gender, 
race, smoking and dietary habits. Determination of normal upper limit of serum 
TSH concentrations to define SCH is also an important factor for these 
variations. 
Prevalence of SCH  
        Our study showed that the prevalence rate of SCH was 7% among the 100 
patients of ACS patients of all clinical severity. These results are in support with 
the study of Cooper and Biondi which reported 4% to 20% as the prevalence of 
SCH in adult population. This vast range could be due to differences in age, 
gender, race, nutritional status of the study populations, availability of Iodine in 
food and dietary intake of Iodine as well as methods used to do assay of serum 
TSH. 87 
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 Regarding age and prevalence of SCH, it was 4.54% in patients who were 
sixty years and above; 8.93% in patients who were below the age of sixty years.  
 Our results were not in concordance with results of NHANES III cohort 
study in which the prevalence increases with increasing age and also with the 
results of Whickham Survey 88 in which higher prevalence of SCH was observed 
in elderly population. But, there was no statistically significant difference in the 
prevalence of SCH between patients who were sixty years and above in 
comparison with patients who were less than sixty years. 
         Our results showing the prevalence 5.56% in males and 10.71% in females 
were also concordant with the that of the Colorado study in which the prevalence 
of SCH in males was 3-16% and  4-21% in females.86 But there was no 
statistically significant difference in the prevalence of SCH between males and 
females.  
        Thyroid profile of Subclinical hypothyroidism was observed in 3 females. 
All of them were post-menopausal women. They had the TSH level of less than 
10μIU/ ml.    
          TSH levels of two SCH patients were above10μIU/ ml. Both of them were 
males.   Mortality was 2.9% in ACS patients (2 out of 69) with euthyroid status 
vs. 0% in those with SCH (p value not significant). 
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Other thyroid function abnormalities 
          Thyroid profile of ESS was found in 16 patients.14 patients were found to 
have low FT₃ levels. Two patients had both FT₄ and FT₃ at lower level. Three 
patients had low FT₄ level. These observations were concordant with studies of 
Vijay K S et al.85 They found 15 ACS patients to have thyroid profile of ESS and 
one patient to have low FT₄ state with normal TSH and FT₃ levels. 
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CONCLUSION 
From this study it is concluded that the prevalence of subclinical 
hypothyroidism in patients presented with Acute Coronary Syndrome is 7% 
 71.43% of SCH was found in ST-elevation ACS patients.       
 28.57% of SCH was found in non ST-elevation ACS patients.  
 In 71.43% of SCH cases lipid profile changes were observed. 
Thyroid profile of Euthyroid sick syndrome was found in 16% of whole 
study population. 
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LIMITATIONS 
 The sample size of the study was small.  
 In the reference range for thyroid profile, age and gender related 
variations were not considered. 
 Variations in thyroid function tests during and after acute illness were 
not considered. FT₃, FT₄ and TSH were performed only once during 
initial hospitalization.   
 Estimation of Troponin -T level was not done to diagnose ST-elevation 
ACS patients who present late for admission. 
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FUTURE PROSPECTS OF THE STUDY 
 
 Since the prevalence of subclinical hypothyroidism in patients with ACS 
was found to be 7% in this study and 71% of them had lipid profile changes, it 
can be considered as a risk factor for Coronary artery heart disease along with 
other risk factors. So thyroid profile can be included in any patient to assess 
cardio vascular risk. Large population studies are needed to confirm it. 
            Screening for subclinical hypothyroidism and assessment of lipid profile 
changes before and after treatment with levothyroxine can be done in risk groups 
like elderly persons, post-menopausal women, persons with family history of 
premature coronary artery heart disease and persons living in places where goiter 
is endemic. 
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CASE PROFORMA 
Date 
Name                                      Age                                     IP NO: 
Address                                  DOA                                     DOD 
Occupation                           
Diet habits 
Past history 
Diabetes Mellitus 
Hypertension 
Thyroid disease 
Other illness  
Medication history 
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Alcoholism 
General examination 
 
Pedal edema/Anemia/Clubbing /Lymphadenopathy 
VITALS: BP:              Pulse Rate:                          weight: 
SYSTEMIC EXAMINATION: 
CVS:                                                                                              Abdomen: 
 
RS:                                                                                                     CNS: 
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Investigations: 
CK MB 
Blood glucose fasting                            PP  glucose 
 
RFT                                    Urea                    Creatinine 
 
Lipid profile     Total cholesterol 
                          Triglyceride 
                          HDL – Cholesterol 
                          Calculated LDL        
 
ECG Rhythm 
ACS Category 
 
Echo cardiogram  
 
Survival 
Thyroid profile 
FT₃ 
FT₄ 
TSH 
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